Nxstage Medical, Inc. (NXTM) Tops Q1 EPS by 2c

Nxstage Medical, Inc. (NASDAQ: NXTM) reported Q1 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $72.2 million versus the consensus estimate of $69.44 million.

NxStage had a strong start to the year and exceeded our guidance across all key metrics," stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage. "The progress we are making on our near term growth drivers is reflected in both strong growth across our business and increasing demand for our innovative new products with patients and customers. Our strategic growth initiatives remain solidly on track and we believe they are positioning the Company toward our goal of 15% annual home revenue growth in 2014."

Guidance:

"After a strong first quarter, we believe we are trending towards the higher end of our annual revenue guidance which was originally set to be between $283 million and $288 million," stated Matthew W. Towse, Chief Financial Officer. "Looking ahead to the second quarter, we expect revenue to be between $70.0 million and $71.5 million, and a net loss in the range of $7.5 million to $6.5 million.

For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery